08:24 AM EDT, 08/05/2025 (MT Newswires) -- Recursion Pharmaceuticals ( RXRX ) reported fiscal Q2 loss Tuesday of $0.41 per diluted share, widening from a $0.40 loss a year earlier.

Analysts polled by FactSet expected a $0.34 loss.

Revenue for the quarter ended June 30 was $19.2 million, up from $14.4 million a year earlier.

Analysts surveyed by FactSet expected $15.4 million.

Recursion shares was up nearly 3% in recent Tuesday premarket activity.